一、本次增资事项概述 汕头市超声仪器研究所股份有限公司（以下简称"公司"）于2025 年4月27日召开第二届董事会第八次会议，审议通过了《关于向子公 司增资的议案》，根据公司的发展战略和全资子公司深圳市汕超科技 有限公司（以下简称"深圳汕超"）的经营管理需要，公司拟以自有 资金人民币50万元对深圳汕超进行增资。本次增资完成后，深圳汕超 的注册资本由人民币50万元增加至人民币100万元，仍为公司全资子 公司。 根据《深圳证券交易所创业板股票上市规则（2024 年修订）》和 《公司章程》等相关规定，本次对外投资在公司董事会审议权限内， 无需提交公司股东会审议。本次对外投资不构成关联交易，也不构成 《上市公司重大资产重组管理办法》规定的重大资产重组。 二、增资标的基本情况 1、公司名称：深圳市汕超科技有限公司 证券代码：301602 证券简称：超研股份 公告编号：2025-018 汕头市超声仪器研究所股份有限公司 关于向子公司增资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 2、成立日期：2015年10月26日 3、注册地址：深圳市福田区梅林街道中康路12 ...

Core Viewpoint - China Galaxy Securities has achieved significant growth in its financial performance, with a net profit exceeding 10 billion yuan and maintaining a strong industry ranking, attributed to strategic reforms and market recovery [1][4]. Financial Performance - In 2024, China Galaxy Securities reported operating revenue of 35.471 billion yuan, ranking fourth in the industry, with a year-on-year growth of 5.43% [4][6]. - The net profit for 2024 reached 10.031 billion yuan, reflecting a year-on-year increase of 27.31%, significantly outperforming the industry average [4][5]. - For Q1 2025, the company anticipates a net profit between 2.773 billion and 3.1 billion yuan, representing a year-on-year growth of 70% to 90% [4][5]. Business Segments - The investment trading business saw a remarkable increase of 45.91%, generating revenue of 6.344 billion yuan, closely linked to the recovery of the stock market [6][7]. - Wealth management revenue surpassed 10 billion yuan, reaching 10.496 billion yuan, with a year-on-year growth of 15.73%, making it the largest contributor to overall revenue [6][7]. - International business and investment banking also experienced growth, with increases of 8.29% and 11.80%, respectively, showcasing resilience amid market challenges [2][15]. Market Context - The overall performance of securities firms in China declined during 2022 and 2023 due to market volatility, but China Galaxy Securities maintained a stable position, leading to an improved ranking [3][4]. - The stock market indices, including the Shanghai Composite and Shenzhen Component, saw increases of 12.7% and 9.3%, respectively, contributing to the positive performance of the securities industry in 2024 [6]. International Expansion - China Galaxy Securities has made significant strides in international business, particularly in Southeast Asia, following the acquisition of local firms and establishing a strong market presence [9][13]. - The company has successfully hosted major financial events, such as the China-ASEAN Business Leaders Summit, enhancing its role as a bridge between Chinese and ASEAN markets [10][11]. Investment Banking Achievements - Despite a general decline in IPOs and refinancing activities in 2024, China Galaxy Securities' investment banking revenue grew by 11.80%, driven by strategic project management and international collaboration [15][16]. - The company successfully facilitated significant transactions, including a major asset restructuring deal valued at 11.5 billion yuan, marking a notable achievement in the investment banking sector [19].

1月22日，汕头市超声仪器研究所股份有限公司（股票代码：301602 简称：超研股份）将在深交所创业板上 市。作为国内超声诊断设备三巨头中成立时间最早的企业，超研股份已走过四十多个春秋，其发展历程正是中 国超声诊断设备自主创新不断发展的缩影。如今，随着医疗、基建相关重大设备"进口替代"进程的加快，以超 研股份为代表的国产超声诊断及工业检测设备厂商正迎来更加广阔的发展空间。 国产超声设备先驱，横跨医疗、工业两大领域 1. 中国医学超声鼻祖，超声影像设备销量排名前三 超研股份成立于1982年，公司前身超声研究所则成立于1978年，是国内唯一一家长期专注于超声设备及无损检 测设备开发的独立研究机构。 医学影像设备主要包括超声、X 射线、CT、MRI 和 PET。其中 超声医学影像设备 （B 超和全数字彩超）及 X 射线设备 （包括 CR、DR 设备等）应用最为广泛，行业内这两种设备占据了医学影像设备约30%以上的市场 份额。 我国医学影像设备行业起步较晚，直到1983年才出现第一台自主研制并量产的B超设备"中华B超"，其正是出 自超研股份之手，因此将超研股份称为中国医学超声鼻祖并不为过。 经过多年发展， 超研股份已 ...